July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Developing pH-dependent cancer-directed synergetic treatment for retinoblastoma
Author Affiliations & Notes
  • Zongchao Han
    Ophthalmology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
    Pharmacoengineering & Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina, United States
  • Ruijuan Gao
    Ophthalmology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
    Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
  • Rajendra Mitra
    Ophthalmology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
  • Min Zheng
    Ophthalmology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
  • Footnotes
    Commercial Relationships   Zongchao Han, None; Ruijuan Gao, None; Rajendra Mitra, None; Min Zheng, None
  • Footnotes
    Support  R01EY026564, the Carolina Center of Nanotechnology Excellence, and the NC TraCS Translational Research Grant (550KR151611)
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1632. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Zongchao Han, Ruijuan Gao, Rajendra Mitra, Min Zheng; Developing pH-dependent cancer-directed synergetic treatment for retinoblastoma. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1632.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Cerium oxide nanoparticle (nanoceria) has unique redox activity in that it possesses antioxidant activity at physiological pH, but has an intrinsic oxidase activity at acidic pH. Therefore, using nanoceria as a base vector for anti-tumor therapy would be a preferred option since it can inhibit cancer cells without damaging fellow normal tissues. We have begun to design a novel antitumor delivery system using a chemotherapy drug and tumor target molecules covalently linked to nanoceria. The goal of this project was to develop nanoceria-assisted combination therapies for tumor-directed treatment of retinoblastoma.

Methods : We constructed a compound (GCCNP-DOX-AMD070), which contains a chemotherapeutic drug (Doxorubincin, DOX) and a tumor selective targeting reagent (AMD070, CXCE4 antagonist) via surface chemistry of our developed water-soluble nanoceria (GCCNP). Dynamic light scattering (DLS) measurements were performed to confirm the successful construction of the compound. Quantitative assessment of in vitro intracellular reactive oxygen species (ROS) production, cell viability, and CXCR4 (a cancer progression marker) expression were performed by DCF, MTT, and Western blot assays at different pH levels in human tumor cell lines (WERI-Bb-1, Y79, A549, and B16F10) and normal human ARPE-19 cells.

Results : We observed strong CXCR4 expressions in all the tumor cell lines but barely in normal ARPE-19 cells. We detected that the GCCNPs increase the production of ROS and reduce cell viability at pH6.5 but not at pH7.4 in all the cell lines that we tested. We found that our combo system markedly suppressed Y79 CXCR4 expression at PH6.5 compared with that treated with DOX only. Interestingly, we did not find the same changes when pH was 7.4, indicating the pH-dependent antitumor behavior of GCCNP-DOX-AMD070.

Conclusions : We have built a novel antitumor delivery system using a chemotherapy drug and tumor target molecules covalently linked to nanoceria. This system is capable of specifically and selectively targeting tumor cells under tumor microenvironment (acidic conditions) but remain stable under normal physiological pH conditions, thus reducing the problems of off-target. The design of nanoceria combo in this application can be custom-built and functionalized to target different diseases by binding the surface of nanoparticles with a cell-specific targeting molecule and therapeutic specificity.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×